10. -- A top shareholder in Valeant Pharmaceuticals ( VRX ), ValueAct Capital, said that there's no need for Valeant to acquire Allergan ( AGN ). A long bidding war is a distraction, ValueAct CEO Jeff Ubben told Reuters in an interview. ValueAct owns 5.7% of Valeant stock and is the company's third-largest stockholder.